Navigation Links
OncoSec Medical to Present at the 25th Annual Roth Conference
Date:3/14/2013

erapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Maine, July 25, 2014  IDEXX Laboratories, Inc. (NASDAQ: ... the second quarter of 2014 increased 11% versus the ... 1 for the second quarter of 2014 versus ... for changes in distributor inventory 2 . Earnings per ... 2014 increased 11% from the prior year period to ...
(Date:7/25/2014)...  Semler Scientific, Inc. (Nasdaq: SMLR ... that develops patented products that assist healthcare providers ... reported financial results for the second quarter and ... "The second quarter of 2014 continued to ... , M.D., chief executive officer of Semler.  "We ...
(Date:7/25/2014)... CHICAGO, Ill., July 25, 2014 NOT ... DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE ... LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ... ended June 30, 2014. "This was another ... earnings per share above our original guidance and announced plans ...
Breaking Medicine Technology:IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33IDEXX Laboratories Announces Second Quarter Results 34Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3
... ARBOR, Mich., Sept. 17 Terumo Heart, ... European Launch Symposium at the European,Association of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO ) (Logo: ... of the European Clinical Trial results for ...
... to enter Phase 2 clinical development, PRINCETON, ... an innovator in the discovery and development of ... a Phase 2a,clinical study of PS433540, the company,s ... and endothelin receptor antagonist,(DARA) that is being developed ...
Cached Medicine Technology:Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
(Date:7/26/2014)... Seattle, Wa (PRWEB) July 26, 2014 ... book review recently updated by Vkool.com, this ... natural and safe methods for treating all ... including:,     Tinnitus due ... subjective tinnitus ,     Nerve pathway tinnitus ...
(Date:7/26/2014)... July 26, 2014 The U.S. Food & ... that includes a new medication guide for AndroGel to include ... side-effect of taking the topical low testosterone medication, notes Wright ... Inc., the makers of the low testosterone theapy drug, has ... pain, swelling or redness as signs of a blood clot ...
(Date:7/26/2014)... Wa (PRWEB) July 26, 2014 According ... updated by Vkool.com, this is a comprehensive guide that ... unwanted tattoos . This book also teaches them ... imitate common medical procedures in their own home for ... that "Get Rid Tattoo Naturally" book includes step-by-step tutorials ...
(Date:7/25/2014)... 2014 2014 Deep Research ... Chromatography Industry” is a professional and in-depth ... Gel Permeation Chromatography market. The report provides ... Permeation Chromatography definition, classification, application, and industry ... This research covers the international market analysis, ...
(Date:7/25/2014)... York (PRWEB) July 25, 2014 A ... summary judgment in two DePuy Pinnacle hip lawsuits ( ... way for the claims to go before a jury ... an opinion rendered on July 18th, U.S. District Judge ... that the two Plaintiffs’ claims may proceed to trial ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... of researchers led by A. K. Rajasekaran, PhD, Director of ... a key protein involved in cell function and regulation is ... work is published online in the American Journal of ... Cigarette smoke is well recognized as a cause of lung ...
... SEATTLE March 21, 2012: Anxiety, depression, stress ... drug use in youth, according to a study from ... researchers from the University of Washington and Seattle University. ... eighth grade who felt more emotional support from teachers ...
... 2012) Ching-Hon Pui, M.D., a renowned leader in the ... the 2012 Pediatric Oncology Award from the American Society of ... better understanding the blood cancer,s biology and treatment as well ... will receive the award in June at the 2012 ASCO ...
... challenges reading in Arabic than native Hebrew or English speakers ... the brain divide the labor differently when the brain processes ... the result of a new study conducted by two University ... Safra Brain Research Center for the Study of Learning Disabilities ...
... Non-small cell lung cancer (NSCLC), the most common form ... chemotherapy. However, a small group of patients can also ... New research published in BioMed Central,s open access journal ... epidermal growth factor receptor (EGFR) using RNAi, alongside TKI ...
... , TUESDAY, March 20 (HealthDay News) ... from the left and right arms might help predict ... new study suggests. Researchers found that people with ... each arm are at higher risk of cardiovascular death ...
Cached Medicine News:Health News:Nemours researchers uncover new evidence of cancer-causing agent present in gaseous phase of cigarette smoke 2Health News:Middle school teacher support lowers risk for early alcohol use 2Health News:ASCO honors Ching-Hon Pui, M.D., for work advancing childhood cancer research and treatment 2Health News:ASCO honors Ching-Hon Pui, M.D., for work advancing childhood cancer research and treatment 3Health News:Brain's involvement in processing depends on language's graphic symbols 2Health News:Brain's involvement in processing depends on language's graphic symbols 3Health News:Double whammy: RNAi enhances lung cancer therapy 2Health News:Blood Pressure Variance Between Arms Points to Heart Risk 2
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the quantitative colorimetric determination of AST (SGOT) in serum....
For the quantitative determination of aspartate aminotransferase in serum. Optimized IFCC procedure without P-5'-P. 500 IU/L at 37C linearity....
... The stainer TST 44 is an ... needed in histology and cytology laboratories. It ... short time. Its again increased large number ... continuous working principle provides a high throughput. ...
Medicine Products: